Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Dermatology | Immunology | Family Medicine
Disease Category: Psoriatic Arthritis
Location: United States, MD

Clinical Trial Details

Overview

Research Study Summary

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses of PDE4 Inhibitor In Subjects With Active Psoriatic Arthritis

Purpose

Do you have Psoriatic Arthritis? You may qualify to participate in a clinical research study.

PDE4 inhibitor
A novel new oral therapy inhibiting PDE4, this agent is active against an intracellular system suppressing a broad array of cytokines resulting in moderate immunomodulation. There is a short placebo controlled randomization period followed by randomization to two strengths of active drug for total treatment period of 5 years. This is a truly unique opportunity for a patient to receive long term care in the context of a study.

To Learn more
Phase

3

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Duration

5 Years

Facility Type

N/A

Contact

The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833

View Map

Research Center Information: The Center for Rheumatology and Bone Research

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 170026

Date Last Changed: July 23, 2013


DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.